The Evidence Library: What the Research Does (and Doesn’t) Show

Most wellness websites tell you what might work. This page tells you what the research actually shows — for every service we sell, including the findings that are inconvenient for us. Every claim below is sorted into one of three tiers, every source was independently verified against its published abstract in July 2026, and where the honest answer is “there is essentially no direct research on this,” we say exactly that. We would rather earn your trust than your quick booking.

How to read the tiers

Supported  consistent findings in decent-quality studies.  Mixed / limited  studies conflict, are small, or show short-lived effects.  Not established  no good evidence — only mechanism, marketing, or anecdote. Nothing on this page is medical advice, and none of our services diagnose or treat any condition.

Common questions, honest answers

These short answers reflect the evidence tiers and sources documented in full below.

Does cryotherapy help anxiety or stress?

That is not established. NOLA Chill does not present whole body cryotherapy as a treatment for anxiety, stress disorders, or any mental-health condition. See the whole body cryotherapy evidence.

Does cryotherapy help migraines or headaches?

That is not established. Whole body cryotherapy should not replace evaluation or treatment for migraines, new headaches, or severe symptoms. See the research and regulatory notes.

Does whole body cryotherapy help arthritis or joint pain?

A treatment benefit is not established. Evidence for whole body cryotherapy does not support presenting it as arthritis or pain treatment. Device-specific clearances for other modalities do not establish claims for WBC.

Is whole body cryotherapy FDA-approved?

No WBC device has been FDA-cleared or approved to treat a medical condition. A device being marketed or installed does not mean the FDA approved therapeutic claims for it.

What does the research say about soreness and recovery?

The evidence is mixed and limited. Some small studies report brief changes in soreness, while reviews rate the evidence low or very low quality. That does not establish faster healing or guaranteed recovery.

Is this medical advice?

No. NOLA Chill is a recovery spa and wellness studio, not a physician-led clinic. We do not diagnose or treat conditions. New, severe, unexplained, or worsening symptoms belong with a licensed clinician.

Whole Body Cryotherapy

Service page →

Supported

No clinical or athletic-performance outcome for whole body cryotherapy currently clears the SUPPORTED bar (consistent findings in decent-quality studies). Published WBC studies use varying research protocols, commonly 2 to 4 minutes at about -110 C to -140 C; those are study conditions, not NOLA Chill equipment settings. NOLA Chill uses a Trident chamber with a studio protocol of 3 to 5 minutes at -110 F. The well-documented responses are an intense cold sensation and a transient drop in skin and tissue temperature, and some users report feeling temporarily refreshed or less sore afterward. These are short-lived subjective sensations, not proven therapeutic benefits.

Mixed / limited

Post-exercise recovery and muscle-soreness relief are MIXED: a handful of small trials suggest short-term soreness reduction, but effects are small, brief, and rated very low quality, with confidence intervals that include no effect. Mood and mental-wellbeing effects are MIXED / preliminary: a 2021 meta-analysis reported promising effect sizes for depressive symptoms, but only from 10 small, heterogeneous studies and the authors called it preliminary. Effects on inflammation markers are inconsistent and short-lived across small studies. Safety is MIXED: a 2023 international scoping review judged documented WBC harms to be limited and manageable when contraindications are followed, but adverse events are poorly monitored in the trial literature and several serious injuries actually involved liquid-nitrogen partial-body units rather than true whole-body cryotherapy.

Not established

There is NO good evidence that whole body cryotherapy treats, cures, heals, or detoxes any disease or condition. The FDA stated it has no evidence WBC effectively treats conditions such as Alzheimer’s, fibromyalgia, migraine, rheumatoid arthritis, multiple sclerosis, anxiety, or chronic pain, and that no WBC device has been FDA-cleared or approved for such uses. The Cochrane review found insufficient (very low quality) evidence that WBC even outperforms simple passive rest for recovery, and it was never compared against established methods such as cold-water immersion. Nearly all recovery research was conducted in young men (60 of 64 pooled participants), so any benefit for women, older adults, or clinical populations is unestablished. Any claim beyond a brief, subjective cold-exposure experience is not supported.

Sources

  1. Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after exercise in adults — Costello et al., 2015, Cochrane Database of Systematic Reviews. Pooling 4 small RCTs (64 participants, 60 male, mean age ~23), the review found only very-low-quality, insufficient evidence that WBC reduces post-exercise muscle soreness or improves subjective recovery versus passive rest; it was not compared against established methods like cold-water immersion, and adverse events were not monitored or reported in any included trial.
  2. A systematic review and meta-analysis of the effect of whole body cryotherapy on mental health problems — Doets et al., 2021, Complementary Therapies in Medicine. Meta-analysis of 10 small, heterogeneous studies (294 participants, 6 RCTs) reported a large within-group and a moderate between-group effect size for depressive symptoms, but the authors characterized this as only preliminary evidence for WBC as an add-on intervention and explicitly called for larger, higher-quality RCTs.
  3. Evaluating safety risks of whole-body cryotherapy/cryostimulation (WBC): a scoping review from an international consortium — Legrand et al., 2023, European Journal of Medical Research. Reviewing documented harms (5 case reports and 2 RCTs, 16 adverse events total), the consortium concluded WBC-specific safety risks appear within acceptable limits when contraindications and guidelines are followed, while noting that several reported serious injuries actually involved partial-body liquid-nitrogen cryotherapy, not true whole-body cryotherapy, and that harms are under-reported.
  4. Whole Body Cryotherapy (WBC): A “Cool” Trend that Lacks Evidence, Poses Risks (FDA Consumer Update) — U.S. Food and Drug Administration, 2016, FDA Consumer Update (fda.gov, now retired/archive-only). The FDA stated it has no evidence that WBC effectively treats any disease or condition (naming Alzheimer’s, fibromyalgia, migraine, rheumatoid arthritis, multiple sclerosis, stress, anxiety, and chronic pain) and that no WBC device has been FDA-cleared or approved; it also warned of frostbite, burns, eye injury, and asphyxiation risk from liquid nitrogen. The page has since been retired from fda.gov and survives only via web-archive captures and reprints.

Regulatory notes

  • FDA Consumer Update, ’Whole Body Cryotherapy (WBC): A “Cool” Trend that Lacks Evidence, Poses Risks,’ published July 5, 2016: the FDA states it has no evidence that WBC effectively treats any disease or condition, and that not a single WBC device has been cleared or approved by the FDA for these uses. This consumer update has since been retired from fda.gov and is available only via web-archive captures and third-party reprints.
  • Per that same 2016 FDA communication, no whole-body cryotherapy device held FDA 510(k) clearance or PMA approval for the marketed wellness or therapeutic claims; FDA-CLEARED / FDA-APPROVED language must not be applied to WBC services.
  • The FDA update also documented physical hazards specific to the modality: frostbite, burns, and eye injury from extreme cold, plus risk of asphyxiation/hypoxia when liquid nitrogen is used to cool the chamber and displaces oxygen.

Localized Cryotherapy

Service page →

Supported

Almost nothing about the marketed benefits of localized cryotherapy sits in the SUPPORTED tier. The only well-established effects are basic biophysics: applying cold to a body area lowers skin and tissue temperature and can produce short-term local numbing/analgesia and vasoconstriction. That is a mechanism, not a proven clinical outcome, and it is transient. No specific recovery, healing, or wellness claim for commercial localized cryotherapy devices is consistently supported by good-quality studies.

Mixed / limited

The effect on muscle soreness and recovery is genuinely mixed, and the honest read leans negative. A 2026 network meta-analysis (Wu et al., 51 RCTs) found local cold therapy gave no significant soreness reduction immediately or at 72h, a modest reduction at 24h, and its largest effect at 48h — but flagged that these rankings rest on indirect comparisons and should be read ’with extra caution.’ A cryotherapy recovery review (Hohenauer et al., 2015) found cooling reduced SUBJECTIVE soreness at 24-96h yet had NO effect on OBJECTIVE markers (creatine kinase, IL-6, lactate), amid high risk of bias and possible placebo. Critically, the one meta-analysis focused specifically on LOCAL cryotherapy (Nogueira et al., 2019) found no significant benefit for soreness or strength at all. Where effects appear, they are small, short-lived, subjective, and confounded by unblinded designs. Most of this literature also studies ice packs, cold-water immersion, or whole-body units — not commercial cold-air/nitrogen ’cryo gun’ devices.

Not established

There is essentially no direct clinical research on the specific commercial service — targeted cold-air or nitrogen-vapor ’cryo gun’ devices applied to a body part at wellness spas. The usable evidence base is on ice/cold packs, cold-water immersion, and whole-body cryotherapy, which are different modalities. No good evidence supports claims that localized cryotherapy detoxifies, burns fat, speeds injury healing, reduces inflammation systemically, boosts metabolism, or treats any medical condition. The FDA states that no cryotherapy device has been cleared or approved to treat any medical condition, and even whole-body cryotherapy — the most-studied form — was judged by a Cochrane review to have insufficient evidence to determine whether it works, with effectiveness and safety unknown.

Sources

  1. Effects of local cryotherapy for recovery of delayed onset muscle soreness and strength following exercise-induced muscle damage: systematic review and meta-analysis — Nogueira et al., 2019, Sport Sciences for Health. Meta-analysis of 7 high-methodological-quality trials found local cryotherapy did NOT significantly accelerate recovery of delayed-onset muscle soreness (effect size -0.11, 95% CI -0.8 to 0.57) or muscle strength (-0.59, 95% CI -2.89 to 1.71) after exercise-induced muscle damage — i.e., no measurable benefit for either outcome.
  2. Impact of different cryotherapy interventions on post-exercise acute delayed-onset muscle soreness, athletic performance, and inflammatory biomarkers: a systematic review and network meta-analysis — Wu et al., 2026, Frontiers in Sports and Active Living. Network meta-analysis of 51 RCTs found local cold therapy produced no significant soreness reduction immediately post-exercise or at 72h, a modest reduction at 24h (outperformed by cold-water immersion), and its greatest reduction at 48h (MD -1.17, 95% CI -2.19 to -0.16), but the authors cautioned that local cold therapy rankings rely on indirect evidence and should be viewed ’with extra caution.’
  3. The Effect of Post-Exercise Cryotherapy on Recovery Characteristics: A Systematic Review and Meta-Analysis — Hohenauer et al., 2015, PLOS ONE. Found post-exercise cooling (predominantly cold-water immersion, not localized cryo) reduced SUBJECTIVE delayed-onset muscle soreness at 24, 48 and 96h (Hedges g -0.71 to -0.75) but had NO effect on objective recovery variables (lactate, creatine kinase, IL-6); authors flagged high or unclear risk of bias and a probable placebo contribution that made interpretation uncertain.
  4. Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after exercise in adults (Cochrane review) — Costello et al., 2016, Journal of Evidence-Based Medicine. Cochrane review of WHOLE-BODY cryotherapy — a different, systemic modality, not localized cold — concluded there is insufficient evidence to determine whether it prevents or reduces muscle soreness after exercise, and that the effectiveness and safety of the intervention remain unknown; included in this library to show even the most-studied cryotherapy form lacks good evidence.

Regulatory notes

  • FDA Consumer Update, ’Whole Body Cryotherapy (WBC): A Cool Trend that Lacks Evidence, Poses Risks’ (published July 5, 2016): the FDA states that no whole-body cryotherapy device has been cleared or approved by the FDA to treat any medical condition, and the agency does not have evidence that WBC effectively treats diseases or conditions such as Alzheimer’s, fibromyalgia, migraines, rheumatoid arthritis, multiple sclerosis, stress, anxiety, or chronic pain. This applies to the broader cryotherapy device category, which includes localized units. No specific 510(k) clearance exists that establishes localized cryotherapy ’cryo gun’ devices as safe and effective for any recovery or medical claim.

Infrared Sauna

Service page →

Supported

The most reliable signal is indirect. Regular heat bathing produces acute relaxation-type physiological responses (raised heart rate, transient blood-pressure change, subjective calm), and large prospective cohorts link frequent sauna use to lower cardiovascular and all-cause mortality (Laukkanen 2015). Crucially, that strongest evidence comes from TRADITIONAL Finnish (dry, high-heat, ~80-100C) sauna, NOT infrared cabins, and it is observational, so it describes an association rather than proof of cause and cannot simply be assumed to transfer to infrared. What is genuinely supported for infrared itself is modest: people generally find sessions relaxing.

Mixed / limited

For infrared saunas specifically, small short-term trials and two reviews (Beever 2009; Hussain & Cohen 2018) suggest possible benefit for blood-pressure normalization, congestive-heart-failure symptoms, and chronic pain, alongside consistently reported relaxation. But the underlying studies are few, small (often fewer than 40 participants), brief, heterogeneous in design, and mostly not randomized (only ~13 RCTs across the entire dry-sauna literature). These effects are plausible but not reliably established, and results conflict or are short-lived.

Not established

Direct, high-quality research on infrared sauna is sparse, and several popular claims are not supported. The reviewed evidence did NOT support cholesterol reduction (Beever 2009 found the data refuted it), and there is no good evidence for ’detox,’ for meaningful lasting weight loss (any drop after one session is water lost through sweat), or for curing or treating any specific disease. Most of the strongest cardiovascular data are from traditional sauna, not infrared, and much of the marketing around infrared rests on small studies or none at all.

Sources

  1. Far-infrared saunas for treatment of cardiovascular risk factors: summary of published evidence — Beever R., 2009, Canadian Family Physician. This infrared-specific review of 9 level I/II studies found only limited-to-moderate evidence that far-infrared sauna helps normalize blood pressure and congestive heart failure and fair evidence (single study) for chronic pain, while the evidence did NOT support cholesterol reduction and manufacturer health claims broadly outran the available data.
  2. Clinical Effects of Regular Dry Sauna Bathing: A Systematic Review — Hussain & Cohen, 2018, Evidence-Based Complementary and Alternative Medicine. Across 40 studies (3,855 participants) of dry sauna bathing including infrared, most reported beneficial effects, but only 13 were randomized trials and most were small (n<40), short, and heterogeneous, so the authors concluded the evidence is too limited to draw firm conclusions and that higher-quality data on benefits and adverse effects are needed.
  3. Association Between Sauna Bathing and Fatal Cardiovascular and All-Cause Mortality Events — Laukkanen et al., 2015, JAMA Internal Medicine. In a prospective cohort of 2,315 middle-aged Finnish men followed a median 20.7 years, more frequent sauna use was associated with dose-dependent lower risk of sudden cardiac death and cardiovascular and all-cause mortality; however, this studied TRADITIONAL dry Finnish sauna (not infrared) and is observational, so it shows association, not proof of cause, and should not be cited as infrared-sauna evidence.

Regulatory notes

  • Far-infrared saunas are noted in the peer-reviewed literature (Beever R, Can Fam Physician 2009;55:691-696) as approved by the Canadian Standards Association (CSA). This is an electrical/manufacturing safety standard, not a health-efficacy endorsement, and does not equate to FDA clearance for any medical benefit.
  • No specific FDA 510(k) clearance for a health/therapeutic benefit of infrared saunas was verified during this research; consumer infrared-heat devices generally fall under FDA’s low-risk infrared lamp classification (temporary relief via topical warming) rather than any cleared indication for the systemic benefits marketed for sauna cabins.

NormaTec Compression Therapy

Service page →

Supported

The single outcome with the most repeated positive signals is a small, short-term reduction in PERCEIVED muscle soreness and an increased pressure-to-pain threshold (people feel less sore / more comfortable) shortly after a session. Honesty caveat: even this is the least-weak signal, not a robust one — the largest meta-analysis rated the soreness effect only ’trivial to moderate,’ and the best-designed placebo-controlled trial found the soreness reduction did NOT reach statistical significance. So the fair claim is experiential: some people report feeling looser and less sore, and studies lean (weakly) in that direction.

Mixed / limited

Effects on muscle strength/power recovery, flexibility / range of motion, and muscle-damage or inflammatory blood markers (creatine kinase, IL-6, CRP) conflict across studies. The largest systematic review and meta-analysis (17 studies, 319 participants) rated benefits to muscular function as ’trivial to small’ and muscle-damage effects as ’highly variable.’ Small, unblinded RCTs report benefits (e.g., improved VAS soreness and some tensiomyography markers) while better-controlled trials do not — a classic sign the effect is small, inconsistent, and sensitive to study design and expectation.

Not established

There is no good evidence that pneumatic compression improves OBJECTIVE performance recovery — the best placebo-controlled trial found no improvement in neuromuscular function, jump performance, or maximal voluntary contraction versus a sham. There is no evidence it ’flushes lactic acid,’ speeds tissue healing, detoxifies, or treats/cures any injury or medical condition. The FDA clearance is only as a powered inflatable tube massager intended to temporarily relieve minor muscle aches/pains and temporarily increase local circulation — not for injury treatment or performance enhancement.

Sources

  1. Effects of lower-limb intermittent pneumatic compression on sports recovery: A systematic review and meta-analysis — Maia et al., 2024, Biology of Sport. Pooling 17 studies (319 participants), lower-limb IPC produced only trivial-to-small benefits for muscular function, a trivial-to-moderate effect on pain/soreness, and highly variable (inconsistent) effects on muscle-damage markers — i.e., its main plausible effect is modestly reducing perceived soreness, not objective recovery.
  2. Intermittent Pneumatic Compression May Reduce Muscle Soreness but Does Not Improve Neuromuscular Function Following Exercise-Induced Muscle Damage: A Randomized Placebo-Controlled Trial — Maia et al., 2025, International Journal of Sports Physiology and Performance. In a placebo-controlled trial, a 30-minute IPC session after exercise-induced muscle damage showed only a non-significant trend toward less perceived soreness (d 0.32-0.75) and produced NO improvement in objective neuromuscular recovery (jump performance, maximal voluntary contraction) versus sham.
  3. Dynamic Compression Enhances Pressure-to-Pain Threshold in Elite Athlete Recovery: Exploratory Study — Sands et al., 2015, Journal of Strength and Conditioning Research. In 24 elite Olympic-training-center athletes randomized to active peristaltic pulse dynamic (NormaTec-type) compression or an inactive control, 15 minutes of compression increased short-term pressure-to-pain threshold, a subjective pain-sensitivity/comfort measure; the study was exploratory and did not standardize the training stimulus, so it reflects perceived pain sensitivity rather than objective recovery.
  4. Effects of intermittent pneumatic compression on delayed onset muscle soreness and recovery of muscular fatigue — Gu et al., 2025, PM&R. In a small RCT of 20 untrained men, IPC applied over 72 hours after plyometric exercise significantly improved perceived soreness (VAS) and two tensiomyography muscle-property markers (Dm, Tc) versus control, but the small, untrained, unblinded sample sharply limits how far the result generalizes.

Regulatory notes

  • NormaTec 3 (NormaTec Industries, LP / Hyperice) is FDA-CLEARED via 510(k) K220217, decision date February 25, 2022, product code IRP (’Powered Inflatable Tube Massager’), Class II under 21 CFR 890.5650 (Physical Medicine) — cleared as a massager to temporarily relieve minor muscle aches/pains and temporarily increase local circulation, NOT to treat injury or enhance athletic performance/recovery.
  • Earlier/predicate NormaTec pneumatic compression devices carry the same powered-inflatable-tube-massager classification (product code IRP), including the NormaTec Pulse 2.0 / Pulse Pro 2.0 (510(k) K183169) and earlier models (e.g., K161346). These are FDA-CLEARED (510(k) substantial-equivalence), which is NOT the same as FDA-approved.

CryoFacial

Service page →

Supported

Very little about a cryofacial is ’supported’ in the study-based sense. The only well-established fact is basic, uncontested physiology: brief cold applied to the face constricts surface blood vessels, which can transiently reduce redness and puffiness and produce a short-lived tightened, cooler-looking appearance. This effect is immediate and reversible — it fades within minutes to hours as vessels re-dilate. It is a temporary sensory/cosmetic experience, not a durable skin change, and even this has not been formally quantified in controlled cryofacial trials.

Mixed / limited

The broader cryotherapy modality — studied mostly as whole-body cryotherapy for exercise recovery and inflammation, not on faces — shows small, short-lived and inconsistent effects on inflammatory markers and subjective recovery, which Cochrane rated as ’very low’ quality evidence. None of this was measured on facial skin, collagen synthesis, pore size, acne, rosacea, or ’glow,’ so applying it to a cryofacial is extrapolation. Marketing claims that a cryofacial boosts collagen, shrinks pores, or improves tone/texture sit here at best: biologically proposed, but not demonstrated for this service.

Not established

There is essentially no direct, peer-reviewed research on the cosmetic ’cryofacial’ — localized cold air or vaporized nitrogen applied to the face for rejuvenation or glow. Claims of lasting anti-aging, collagen stimulation, permanent pore reduction, ’detox,’ or treatment of acne/rosacea are anecdotal and marketing-driven, not evidence-based. Regulators and dermatologists are openly skeptical of the wider category: the FDA found ’very little evidence’ for cryotherapy’s effectiveness and notes no cryotherapy device has been cleared or approved for such claims, and dermatology bodies warn the benefits are unproven while documenting real skin risks (frostbite, cold burns, cold panniculitis). Honest bottom line: a cryofacial is generally a pleasant, low-risk experience when done carefully, but any durable skin benefit is not established.

Sources

  1. Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after exercise in adults — Costello et al., 2015, Cochrane Database of Systematic Reviews. This systematic review found insufficient, very-low-quality evidence that whole-body cryotherapy reduces muscle soreness or improves recovery, and it examined athletic recovery — not facial skin, collagen, or any cosmetic outcome, so it cannot support cryofacial claims.
  2. Evaluating safety risks of whole-body cryotherapy/cryostimulation (WBC): a scoping review from an international consortium — Legrand et al., 2023, European Journal of Medical Research. This scoping review catalogued 16 WBC adverse events (e.g., cold panniculitis, urticaria, headaches/dizziness, plus rare serious events such as transient global amnesia and intracerebral hemorrhage), judged adverse events likely under-reported, and concluded overall that WBC-related safety risks are ’within acceptable limits’ and largely preventable via existing contraindications; it establishes no cosmetic benefit, and the frequently-cited cold-burn case in the literature involved a partial-body cryosauna rather than true whole-body cryotherapy.
  3. Whole Body Cryotherapy (WBC): A “Cool” Trend that Lacks Evidence, Poses Risks — U.S. FDA (Consumer Update), 2016, FDA Consumer Update. The FDA stated it found ’very little evidence’ for cryotherapy’s safety or effectiveness for the conditions it is marketed to address, and that not a single whole-body cryotherapy device has been cleared or approved by the agency for these claims.

Regulatory notes

  • FDA Consumer Update (July 2016), ’Whole Body Cryotherapy (WBC): A “Cool” Trend that Lacks Evidence, Poses Risks’: the FDA informally reviewed the published literature and found very little evidence about WBC’s safety or effectiveness for the conditions it is promoted for (e.g., arthritis, fibromyalgia, chronic pain, anxiety).
  • Per that same 2016 FDA Consumer Update: no whole-body cryotherapy device has been cleared or approved (no 510(k) clearance or approval) by the agency in support of these therapeutic claims. No FDA clearance exists establishing cosmetic cryofacial skin-rejuvenation claims either.

CryoSlim Body Contouring

Service page →

Supported

For TRUE cryolipolysis delivered by FDA-cleared vacuum-applicator systems (CoolSculpting/Zeltiq), which suction a fat fold and hold it at sub-zero temperatures for roughly 35-60 minutes, multiple systematic reviews find a modest, measurable reduction in localized subcutaneous fat thickness at the treated site: on the order of ~15-28% by caliper and ~10-32% by ultrasound across reviews. A 2025 meta-analysis confirms significant reductions in local fat thickness, treated-area circumference, and BMI. Reviews consistently report no significant changes in serum lipids or liver-function tests, and side effects that are usually mild and transient (redness, swelling, temporary numbness). This is localized contouring of a treated area, not a general slimming or weight-loss effect.

Mixed / limited

Effect sizes vary widely by body region, applicator/device generation, and follow-up length, and benefits are most pronounced in short-term follow-up; results are modest and not equivalent to surgical fat removal. On safety, paradoxical adipose hyperplasia (PAH) – where the treated fat enlarges instead of shrinking – is a genuine, well-documented adverse event. Its true incidence is higher than manufacturer marketing implies: a multicenter review of 8,658 cycles found PAH in ~0.15% of cycles (~0.43% of patients), several times the manufacturer’s quoted 0.025%, and multiple sources note it is likely underreported (with some estimates ranging higher). Newer-generation applicators appear to reduce PAH occurrence substantially.

Not established

The controlled-trial and meta-analysis evidence base is almost entirely for FDA-CLEARED cryolipolysis applicator systems. It does NOT transfer to handheld ’cryo slimming’/’cryo sculpting’ wand devices (e.g., Kaasen-style units) that sweep the skin surface at roughly 0-4°C; there is essentially no peer-reviewed controlled-trial evidence that these moving-wand devices produce durable fat-cell reduction, despite spa marketing that borrows the ’cryolipolysis’ and ’apoptosis’ language and sometimes claims ’FDA-cleared’ without a fat-reduction 510(k). If a specific CryoSlim service uses a wand-style device rather than a cleared suction-applicator system, the supported findings above should not be assumed to apply to it. Additionally: cryolipolysis of any kind is not a weight-loss method (meta-analysis found no significant change in body weight), does not detox, eliminate toxins, or boost immunity, and its long-term (multi-year) durability is not well characterized in the literature.

Sources

  1. Cryolipolysis for Fat Reduction and Body Contouring: Safety and Efficacy of Current Treatment Paradigms — Ingargiola et al., 2015, Plastic and Reconstructive Surgery. Systematic review of 19 studies of applicator-based cryolipolysis (CoolSculpting/Zeltiq) found modest localized fat reduction (~14.67-28.5% by caliper, 10.3-25.5% by ultrasound) with only mild, short-term side effects and no significant impact on serum lipids or liver-function tests, alongside a single documented case of paradoxical adipose hyperplasia.
  2. Cryolipolysis in the United States-Review of the clinical data — Hetzel et al., 2023, Journal of Cosmetic Dermatology. Review of 18 US clinical studies concluded cryolipolysis is a safe but only ’modestly effective’ method of reducing focal fat (ultrasound fat-thickness reduction 19.6-32.3%, caliper 14.9-21.5%), documented four cases of paradoxical adipose hyperplasia across 3,453 treatment cycles, and explicitly flagged the limited quantity and quality of US research.
  3. Effectiveness of Cryolipolysis in Body Contouring and Fat Reduction: A Systematic Review and Meta-analysis — Hakami et al., 2025, World Journal of Plastic Surgery. Meta-analysis found cryolipolysis significantly reduced local fat thickness (MD -3.56 mm), treated-area circumference (MD -3.45 cm), and BMI (MD -1.71), but found NO statistically significant change in body weight (MD -1.81, P=0.09), with effects more pronounced at short-term follow-up – supporting targeted contouring rather than weight loss.
  4. A Multicenter Evaluation of Paradoxical Adipose Hyperplasia Following Cryolipolysis for Fat Reduction and Body Contouring: A Review of 8658 Cycles in 2114 Patients — Nikolis et al., 2021, Aesthetic Surgery Journal. Across 8,658 cryolipolysis cycles in 2,114 patients, paradoxical adipose hyperplasia occurred in 0.15% of cycles (0.43% of patients) – roughly six times the manufacturer’s quoted 0.025% rate and higher than commonly cited – though newer-generation applicators reduced occurrence by over 75%.

Regulatory notes

  • True cryolipolysis devices are FDA-CLEARED (via de novo / 510(k)), not FDA-approved. Zeltiq/CoolSculpting received de novo clearance DEN090002 for the flanks (Aug 24, 2010), followed by 510(k) clearances for the abdomen (K120023, 2012), thighs (K133212, 2014), submental area (K151179, 2015), and later areas including bra/back/banana-roll fat (K160259), upper arms (K162050), and the submandibular area (K181740). These K-numbers are verifiable in the FDA 510(k)/de novo database at accessdata.fda.gov.
  • The FDA classifies cryolipolysis fat-reduction devices as prescription-use only and states that the safety and effectiveness of over-the-counter or home-use ’fat freezing’ devices has not been established.
  • A general cryotherapy or ’cryo’ device clearance is not the same as a clearance for fat-layer reduction; a spa’s ’FDA-cleared’ claim for a ’cryo slimming’ service should be checked against a specific 510(k)/K-number for non-invasive fat reduction, because the published fat-reduction evidence pertains to suction-applicator cryolipolysis systems, not moving-wand cryotherapy devices.

NuCalm

Service page →

Supported

Nothing NuCalm-specific reaches the SUPPORTED bar. There are no systematic reviews, no meta-analyses, and no independent sham-controlled RCTs of NuCalm. The only thing well established in the broader literature is the general, non-NuCalm principle that guided relaxation and downregulating sympathetic arousal can produce short-term subjective calm and modest short-term HRV shifts — but that research does not test NuCalm, its GABA discs, or its neuroacoustics, so it cannot be cited as support for this specific product.

Mixed / limited

The most that has any peer-reviewed signal is experiential: feeling calmer during a procedure. In a small retrospective chart review (Marino 2019, N=25), self-reported anxiety dropped during office nasal procedures done under NuCalm plus local anesthesia (p=0.005). But that study had no control group, so placebo, expectation, and natural settling cannot be excluded, and pain scores did NOT significantly improve. This is weak, uncontrolled, single-study evidence — enough to describe a relaxing subjective experience for some people, not enough to claim NuCalm caused it.

Not established

NuCalm’s marketed mechanistic and clinical claims are NOT established: that GABA ’electromagnetic frequency’ discs, neuroacoustic software, or historical cranial electrotherapy measurably produce ’parasympathetic dominance’ or reduce anxiety, depression, or improve sleep. The only depression/anxiety data (Sunder 2025) is an n=3 case series in which NuCalm was inseparably combined with rTMS, so nothing can be attributed to NuCalm. NuCalm holds real patents, but a patent proves legal novelty, not that a device works. Bottom line: direct, high-quality, independent research on this specific service essentially does not exist — the published human evidence is two tiny, uncontrolled reports totaling 28 patients, plus low-tier signal-analysis papers. Never state or imply it treats, cures, or heals any condition.

Sources

  1. Nonpharmacological Relaxation Technology for Office-Based Rhinologic Procedures — Marino et al., 2019, ORL J Otorhinolaryngol Relat Spec. In a retrospective chart review of 25 patients undergoing office-based rhinologic procedures with the NuCalm system plus local anesthesia, self-reported anxiety fell from 2.00 pre-op to 1.25 post-op (p=0.005), but there was no control group and pain scores did not significantly change (p=0.054), so the anxiety drop cannot be attributed to NuCalm over placebo, expectation, or natural settling.
  2. Coupling Bio-Resonance Neurotechnology (BRNT) and Dual Hemispheric Repetitive Transcranial Magnetic Stimulation (rTMS) Reduces Comorbid Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) as Demonstrated by PHQ-9 and GAD-7: Pilot Case Series — Sunder et al., 2025, Psychology Research and Behavior Management. A retrospective pilot case series of just 3 patients reported large PHQ-9 and GAD-7 reductions, but NuCalm (BRNT) was delivered simultaneously with dual-hemispheric rTMS, so no effect can be isolated to NuCalm; it is hypothesis-generating at most.
  3. Systems and methods for balancing and maintaining the health of the human autonomic nervous system (US Patent 9,079,030 B2) — Holloway (Solace Lifesciences), 2015, US Patent and Trademark Office. This granted patent documents NuCalm’s combination of GABA/neurotransmitter supplementation, cranial electrotherapy stimulation, neuroacoustic entrainment, and light-blocking, and establishes the legal novelty of the method; it is not a study and provides no clinical evidence that the system reduces anxiety or improves any health outcome.

Regulatory notes

  • US Patent 9,079,030 B2, granted July 14, 2015 to Solace Lifesciences Inc. (verifiable at patents.google.com/patent/US9079030B2), describes combining GABA/neurotransmitter supplementation, cranial electrotherapy stimulation, neuroacoustic binaural-beat entrainment, and light-blocking. A granted patent establishes legal novelty of the method only; it is NOT evidence of clinical efficacy.
  • FDA reclassified cranial electrotherapy stimulator (CES) devices intended to treat anxiety and/or insomnia from Class III to Class II, effective December 20, 2019 (Federal Register doc 2019-27295); CES devices intended to treat depression remain subject to premarket approval (PMA). This is a general CES regulatory fact — the original NuCalm included a CES component. A NuCalm-specific FDA 510(k) clearance number could not be verified, so no NuCalm-specific FDA clearance is asserted here.

Hydromassage

Service page →

Supported

What is supported concerns hands-on manual massage delivered by a therapist, NOT the water-jet bed itself. Meta-analytic evidence finds a single session of manual massage reduces state anxiety, blood pressure, and heart rate, and a course of treatment produces the largest effects on trait anxiety and depression (Moyer 2004); a separate systematic review of RCTs finds manual massage reduces pain versus no treatment (strong recommendation) though only weakly versus sham/active comparators (Crawford 2016). CRITICAL caveat: every one of these findings is for human-hands massage, not a hydromassage bed. Whether the relaxation experience transfers to lying clothed on a warm water-jet table is not something these studies tested, so at most they support the idea that a massage-like experience can feel calming in the short term.

Mixed / limited

The only published research on water-jet massage as a modality is thin and its results cut both ways. A small crossover study (n=14 athletes) of warm underwater water-jet massage found it helped maintain neuromuscular performance across a week of intense training, but it also INCREASED the release of muscle proteins (myoglobin) into the blood rather than reducing muscle damage (Viitasalo 1995). So even the closest available water-jet evidence is small, uses water immersion rather than a dry hydromassage bed, and does not show a clean recovery benefit.

Not established

There is essentially no direct, good-quality published research on the dry hydromassage bed itself (the service where you stay clothed and dry on a barrier over pulsating water jets). Independent insurer clinical reviews classify dry hydrotherapy/hydromassage as experimental, investigational, or unproven, stating flatly that there is no reliable peer-reviewed published literature on it (Aetna CPB 0699, 2025). No claim that a hydromassage bed treats, cures, relieves, or heals any medical condition is supported by evidence. The honest position: it may be a pleasant, relaxing experience, but the specific device has not been shown in published trials to do more than that, and any benefit is inferred from general manual-massage research that may not transfer to a machine.

Sources

  1. Warm underwater water-jet massage improves recovery from intense physical exercise — Viitasalo et al., 1995, European Journal of Applied Physiology and Occupational Physiology. In a small crossover study of 14 junior athletes, three 20-minute warm underwater water-jet massage sessions during an intense training week helped maintain jumping power and neuromuscular performance better than a no-massage control week, but paradoxically INCREASED serum myoglobin (more muscle protein leaking into the blood) rather than reducing muscle damage; it also used water immersion, not a dry hydromassage bed.
  2. A meta-analysis of massage therapy research — Moyer et al., 2004, Psychological Bulletin. Pooling 37 studies of hands-on manual massage, single sessions significantly reduced state anxiety, blood pressure, and heart rate but showed NO significant effect on negative mood, immediate pain, or cortisol; the largest effects were reductions in trait anxiety and depression after a course of treatment. Applies to manual massage, not water-jet beds.
  3. The Impact of Massage Therapy on Function in Pain Populations—A Systematic Review and Meta-Analysis of Randomized Controlled Trials: Part I, Patients Experiencing Pain in the General Population — Crawford et al., 2016, Pain Medicine. Across ~67 RCTs of manual massage, the authors gave a strong recommendation for massage to reduce pain versus no treatment but only a weak recommendation versus sham or active comparators, and weak recommendations for anxiety and quality of life; benefit shrank against active treatments. This is manual therapist-delivered massage, so relevance to a hydromassage bed is indirect.
  4. Dry Hydrotherapy (Hydromassage, Aquamassage, Water Massage) — Clinical Policy Bulletin 0699 — Aetna (CPB 0699), 2025, Aetna Clinical Policy Bulletin. This insurer clinical review (last reviewed 10/14/2025) classifies dry hydrotherapy/hydromassage as experimental, investigational, or unproven, stating there is ’no reliable peer-reviewed published literature on dry hydrotherapy’ and that well-designed RCTs are needed to demonstrate any benefit — the primary evidence that direct research on this specific service is essentially absent.

Regulatory notes

  • Aetna Clinical Policy Bulletin (CPB) 0699, most recently reviewed 10/14/2025, classifies dry hydrotherapy (also called hydromassage, aquamassage, or water massage) as ’experimental, investigational, or unproven because there is insufficient scientific evidence on the effectiveness of this intervention,’ and states ’There is no reliable peer-reviewed published literature on dry hydrotherapy.’
  • Dry hydrotherapy / hydromassage devices (e.g., HydroMassage-branded beds, formerly AquaMED; SolaJet; Wellsystem/Hydrojet) are regulated by the FDA as Class I ’therapeutic massagers’ under 21 CFR 890.5660 (product code ISA). Class I therapeutic massagers are exempt from 510(k) premarket notification and require NO submission of clinical efficacy data. Therefore these beds are neither FDA-approved nor FDA-cleared for effectiveness — marketing must not imply otherwise.

Celluma LED Therapy

Service page →

Supported

Photobiomodulation with red and near-infrared light has a plausible, well-characterized mechanism (light absorption by mitochondrial cytochrome c oxidase driving cellular effects). For musculoskeletal PAIN, a Lancet meta-analysis of 16 RCTs (Chow 2009) found low-level therapy reduced neck pain immediately after treatment and up to 22 weeks later in chronic cases; blue-light and red/NIR devices in this class (including Celluma) are FDA-CLEARED (510(k) K131113) for temporary relief of minor muscle and joint pain and for reducing mild-to-moderate inflammatory acne. Two important caveats: the strongest pain evidence used medical LASERS, not LED panels, and 510(k) clearance means only ’substantially equivalent to a predicate device,’ NOT proof that the device works.

Mixed / limited

For skin rejuvenation (wrinkles, collagen, roughness) and wound/tissue healing, individual studies report benefits, but the evidence is dominated by small, single-center, methodologically weak trials using highly heterogeneous wavelengths, fluences, and protocols. Review authors (Avci 2013; Glass 2023) explicitly note that many published LLLT studies report NEGATIVE results, that dosimetry varies enormously, and that heterogeneity was severe enough to preclude quantitative meta-analysis — so real-world effect sizes, the optimal dose, and durability remain uncertain.

Not established

There is essentially no independent, high-quality randomized evidence that the specific Celluma device delivers the broad ’anti-aging,’ ’recovery,’ or general-wellness benefits often marketed in spa settings, and long-term durable benefit and device-specific superiority over a credible sham are not established for most consumer uses. Critically, FDA CLEARANCE is not FDA APPROVAL: a 510(k) is a determination of substantial equivalence to an earlier marketed device and does not certify efficacy — Celluma itself states it is ’cleared,’ not ’approved.’

Sources

  1. Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring — Avci et al., 2013, Seminars in Cutaneous Medicine and Surgery. This widely cited narrative review describes the photobiomodulation mechanism and dermatologic applications of LLLT but explicitly cautions that studies vary enormously in dosimetry parameters, that fundamental mechanisms remain uncertain, and that many published LLLT studies report negative results (attributed to poor wavelength/dose choices rather than proven inefficacy).
  2. Photobiomodulation: A Systematic Review of the Oncologic Safety of Low-Level Light Therapy for Aesthetic Skin Rejuvenation — Glass, 2023, Aesthetic Surgery Journal. This systematic review concluded photobiomodulation appears oncologically safe for aesthetic skin rejuvenation and found no evidence it must be avoided by prior cancer patients, but it explicitly noted that most clinical data come from methodologically flawed single-center trials and case series with heterogeneous parameters, making a quantitative meta-analysis impossible and large rigorous RCTs unlikely to appear soon.
  3. Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis of randomised placebo or active-treatment controlled trials — Chow et al., 2009, The Lancet. This meta-analysis of 16 RCTs (820 patients) found low-level LASER therapy reduced pain immediately after treatment in acute neck pain and for up to 22 weeks after treatment in chronic neck pain; however, the trials were heterogeneous in wavelength and dose and used medical lasers rather than LED panels like Celluma, and later commentators questioned its use of a fixed-effects model given that heterogeneity.

Regulatory notes

  • FDA 510(k) K131113 (applicant Biophotas, Inc.; device ’BIOPHOTAS CELLUMA’): decision date January 15, 2014; product code ILY; regulation 21 CFR 890.5500; Class II. Cleared to deliver topical heating for temporary relief of minor muscle and joint pain, arthritis, and muscle spasm; relieving stiffness; promoting relaxation of muscle tissue; and temporarily increasing local blood circulation. The blue-light (~463-465 nm) component is cleared to reduce mild-to-moderate inflammatory acne vulgaris. Device delivers red (~640 nm), near-infrared (~880 nm), and blue wavelengths.
  • FDA 510(k) ’clearance’ is a determination that a device is SUBSTANTIALLY EQUIVALENT to a legally marketed predicate device; it is NOT the same as FDA ’approval’ and does not require independent proof of efficacy. Celluma’s own materials state the device is ’FDA cleared’ (not ’FDA approved’) and distinguish the two.
  • Additional BioPhotas Celluma 510(k) submissions appear in the FDA accessdata database (e.g., K171323, K211038); their specific cleared indications are not listed here because they were not independently verified for this page.

Methodology

Sources were selected preferring systematic reviews and meta-analyses, then landmark trials and regulatory documents. Each citation was independently re-verified in July 2026: the identifier (PMID/DOI) was resolved, the title confirmed, and the stated finding checked against the published abstract — including the direction of results. Citations that could not be verified were discarded rather than kept. Tier assignments follow the definitions above and err toward the more conservative tier.

More from our data desk

New Orleans Heat & Recovery Index · Running in New Orleans Heat: Month-by-Month Almanac · US South Cryotherapy Price Index

Cite this page

Free to reference with attribution. Suggested citation:

NOLA Chill (2026). The Evidence Library: what research does and does not show about recovery services. Retrieved from https://nolachill.com/evidence-library/

Last verified: July 15, 2026. Reviewed and refreshed semiannually by NOLA Chill.